Skip to content

Mobile Health-based Motivational Interviewing to Promote COVID-19 Vaccination

Mobile Health-based Motivational Interviewing to Promote Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Oklahomans

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05977192
Acronym
COVID-19
Enrollment
60
Registered
2023-08-04
Start date
2024-04-01
Completion date
2025-03-01
Last updated
2025-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaccination Hesitancy

Brief summary

The objective of this study is to evaluate the preliminary efficacy and acceptability of an mobile Health-based motivational interviewing (MI) intervention to promote SARS-CoV-2 vaccination (MOTIVACC) compared to traditional phone-based MI.

Interventions

BEHAVIORALStandard MI

One phone-based MI session

BEHAVIORALIntensive MI

Four phone-based MI sessions

BEHAVIORALMOTIVACC

mHealth-based MI

BEHAVIORALEcological momentary assessment (EMA) messages

EMA messages focused on vaccinations and health

Sponsors

University of Oklahoma
CollaboratorOTHER
Oklahoma State University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* \>18 years * Reside in a rural area * No previous dose of a SARS-CoV-2 vaccine * Speak English * Able to provide informed consent

Exclusion criteria

* A cognitive or other disability that inhibits smart phone use * Inability to participate because of medical or psychiatric conditions diagnosed by a physician/clinician * Enrollment in other COVID-19 research; pregnant or lactating

Design outcomes

Primary

MeasureTime frame
Changes in intention to receive the vaccineBaseline and follow-up (8 weeks)
Changes in vaccine hesitancy and confidenceBaseline and follow-up (8 weeks)

Secondary

MeasureTime frame
Changes in ambivalenceBaseline and follow-up (8 weeks)
Changes in value-behavior discrepancyBaseline and follow-up (8 weeks)
Changes in expectations related to vaccinesBaseline and follow-up (8 weeks)
Number of participants who receive the COVID-19 vaccineFollow-up (8 weeks)
Changes in self-efficacyBaseline and follow-up (8 weeks)

Other

MeasureTime frame
Percentage of total of ecological momentary assessment messages opened/viewed8 weeks (from baseline to follow up)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026